<DOC>
	<DOCNO>NCT01084174</DOCNO>
	<brief_summary>The purpose study explore safety efficacy sublingual ( tongue ) immunotherapy ( SLIT ) dose regimen oral immunotherapy ( OIT ) regimen induce desensitization long term tolerance child persistent peanut allergy .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Pilot Study Sublingual/Oral Immunotherapy Treatment Peanut Allergy</brief_title>
	<detailed_description>To effectively address Primary Objectives pilot study , 30 subject age 6-21 year : ( 1 ) convince clinical history peanut allergy ( PA ) , ( 2 ) serum immunoglobulin E ( IgE ) specific peanut &gt; 0.35 kilo unit per liter ( kU/L ) skin prick test ( SPT ) wheal &gt; 3 mm , enrol . Subjects recruit Johns Hopkins Pediatric Allergy Clinic . Participants undergo initial screen visit include medical history , physical exam , skin testing , phlebotomy . Informed consent assent obtain . At next two visit , 20 participant complete double-blind placebo-controlled food challenge ( DBPCFC ) . Eligible subject randomize 1:1 ratio two group . One group receive active SLIT placebo OIT group begin active OIT placebo SLIT dose escalation . Over next 16 week study , subject undergo SLIT OIT dose increase . A maintenance dose take home daily 12 month . A DBPCFC complete 6 month 12 month home dosing . Those patient pass DBPCFC take SLIT OIT 4 week . A final challenge administered end period . Ten additional peanut-allergic subject age 6-21 year enrol follow longitudinal control mechanistic study . These subject follow modify schedule compare subject receive study treatment evaluate phlebotomy , end point titration prick skin testing , saliva collection . These patient continue strict avoidance peanut unless otherwise advise personal physician .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>Are age 6 21 year either sex , race , ethnicity time initial visit . Have physician diagnose peanut allergy convince clinical history peanut allergy ( urticaria , upper low respiratory symptom , GI disturbance , rash oral symptom ) . Have skin prick test positive peanut ( diameter wheal 3 mm ≥ negative control ) detectable serum peanutspecific IgE level ( UniCAP ≥ 0.35 kU/L ) . Have positive reaction cumulative dose ≤1,000 mg peanut powder initial qualify DBPCFC . Use effective method contraception female childbearing potential prevent pregnancy agree continue practice acceptable method contraception duration participation study . Ability perform spirometry maneuver accordance American Thoracic Society ( ATS ) guideline ( 1994 ) . Have selfinjectable epinephrine ( i.e . EpiPen® EpiPen Jr.® ) available time . Provide sign informed consent ( parent legal guardian subject minor ) inform assent applicable . Have history severe anaphylaxis peanut hypoxia ( cyanosis peripheral capillary oxygen saturation ( SpO2 ) ≤92 % stage ) , hypotension neurological compromise ( confusion , collapse , loss consciousness incontinence ) . Tolerates 1,000 mg peanut powder initial qualify DBPCFC . Have viral upper respiratory infection ( URI ) gastroenteritis within 7 day OFC ( OFC need reschedule ) . Currently participate study use investigational new drug . Participation interventional study treatment food allergy past 12 month . Pregnancy lactation Allergy placebo ingredient ( Glycerin oat flour ) OR react dose placebo qualify OFC . Currently buildup phase allergy immunotherapy . Poor control atopic dermatitis . Have pulmonary function test force expiratory volume 1 ( FEV1 ) value &lt; 80 % predict clinical feature great moderate persistent asthma great high daily dos inhale corticosteroid ( &gt; 500µg/day fluticasone equivalent ) . Use steroid medication ( oral steroid , prednisone Medrol , steroid injection , Kenalog , IV oral corticosteroid burst ) follow manner : History daily oral steroid dose within 4 week prior baseline visit &gt; 1 month past year burst oral steroid course past 6 month &gt; 1 burst oral steroid course past year . Asthma require ≥1 hospitalization past year asthma &gt; 1 ER visit past 6 month asthma Use omalizumab nontraditional form allergen immunotherapy ( e.g. , oral sublingual ) immunomodulatory therapy ( include corticosteroid ) biologic therapy within past year . Use βblockers ( oral ) , angiotensinconverting enzyme ( ACE ) inhibitor , angiotensinreceptor blocker ( ARB ) , calcium channel blocker tricyclic antidepressant therapy . Inability discontinue antihistamine 5 day long act 3 day short act prior skin test OFC 's . History alcohol drug abuse . Active eosinophilic gastrointestinal disease past two year . Have significant medical condition ( e.g. , liver , gastrointestinal , kidney , cardiovascular , pulmonary disease , blood disorder ) , opinion Investigator , make subject unsuitable induction food reaction . Any previous intubation due allergy asthma . Severe reaction initial DBPCFC , define : Lifethreatening anaphylaxis Requiring overnight hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peanut Allergy</keyword>
</DOC>